BioCentury
ARTICLE | Clinical News

Sustol: Phase III data

July 20, 2015 7:00 AM UTC

Top-line data from the double-blind, U.S. Phase III MAGIC trial in 942 patients receiving highly emetogenic chemotherapy showed that 500 mg subcutaneous Sustol met the primary endpoint of a greater proportion of patients achieving a complete response, defined as no emesis and no rescue medication use 24-120 hours following chemotherapy, vs. IV ondansetron (64.7% vs. 56.6%, p=0.014). Sustol also increased the proportion of patients achieving complete control, defined as a complete response plus no more than mild nausea 24-120 hours following chemotherapy, vs. IV ondansetron (p=0.022). Additionally, Sustol increased the proportion of patients who experienced no nausea or infrequent nausea 24-120 hours following chemotherapy vs. IV ondansetron (p=0.032). Sustol was well tolerated. Patients also received IV fosaprepitant and IV dexamethasone. ...